Medicamen Biotech Limited

NSE MEDICAMEQ.NS

Medicamen Biotech Limited EBITDA Margin for the year ending March 31, 2024: 13.70%

Medicamen Biotech Limited EBITDA Margin is 13.70% for the year ending March 31, 2024, a -30.36% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Medicamen Biotech Limited EBITDA Margin for the year ending March 31, 2023 was 19.67%, a -12.00% change year over year.
Medicamen Biotech Limited EBITDA Margin for the year ending March 31, 2022 was 22.35%, a 23.36% change year over year.
Medicamen Biotech Limited EBITDA Margin for the year ending March 31, 2021 was 18.12%, a 6.22% change year over year.
Medicamen Biotech Limited EBITDA Margin for the year ending March 31, 2020 was 17.06%, a -0.96% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: MEDICAMEQ.NS

Medicamen Biotech Limited

CEO	Mr. Rajesh Madan B. Pharma
IPO Date	Oct. 27, 2021
Location	India
Headquarters	1506, Chiranjiv Tower
Employees	378
Sector	Health Care
Industries Pharmaceuticals

Description

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.

Key trends

Past 5 years